Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Cash from Financing Activities over the past 10 years, most recently at $394.2 million for Q4 2025.

  • Quarterly Cash from Financing Activities rose 13285.13% to $394.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $478.0 million through Dec 2025, up 19.8% year-over-year, with the annual reading at $478.0 million for FY2025, 19.8% up from the prior year.
  • Cash from Financing Activities was $394.2 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $2000.0 in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $491.9 million in Q3 2022 and troughed at -$722000.0 in Q1 2023.
  • The 5-year median for Cash from Financing Activities is $11.9 million (2021), against an average of $94.2 million.
  • The largest YoY upside for Cash from Financing Activities was 17459.4% in 2023 against a maximum downside of 144.79% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $85.7 million in 2021, then tumbled by 97.8% to $1.9 million in 2022, then skyrocketed by 17459.4% to $330.5 million in 2023, then crashed by 99.11% to $2.9 million in 2024, then skyrocketed by 13285.13% to $394.2 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash from Financing Activities are $394.2 million (Q4 2025), $2000.0 (Q3 2025), and $83.6 million (Q2 2025).